Access content directly

Nicolas Azzopardi




Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX)

David Tougeron , Sheik Emambux , Laure Favot , Thierry Lecomte , Ewa Wierzbicka-Hainaut
OncoImmunology, 2020, 9 (1), 15 p. ⟨10.1080/2162402X.2020.1848058⟩
Journal articles hal-03149030v1
Image document

In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration

Thomas Secher , Emilie Dalonneau , Marion Ferreira , Christelle Parent , Nicolas Azzopardi
Journal of Controlled Release, 2019, 303, pp.24-33. ⟨10.1016/j.jconrel.2019.04.005⟩
Journal articles hal-02179896v1

Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited

Amina Bensalem , Denis Mulleman , Gilles Paintaud , Nicolas Azzopardi , Valerie Gouilleux-Gruart
Clinical Pharmacokinetics, 2019, ⟨10.1007/s40262-019-00826-5⟩
Journal articles hal-02316414v1

CD4+ count‐dependent concentration‐effect relationship of rituximab in rheumatoid arthritis

Amina Bensalem , Denis Mulleman , Gilles Thibault , Nicolas Azzopardi , Philippe Goupille
British Journal of Clinical Pharmacology, 2019, ⟨10.1111/bcp.14102⟩
Journal articles hal-02376303v1
Image document

Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans

David Ternant , Nicolas Azzopardi , William Raoul , Theodora Bejan-Angoulvant , Gilles Paintaud
Clinical Pharmacokinetics, inPress, ⟨10.1007/s40262-018-0680-3⟩
Journal articles hal-01821717v1

Cetuximab pharmacokinetics influences overall survival in head and neck cancer patients

Yoann Pointreau , Nicolas Azzopardi , David Ternant , Gilles Calais , Gilles Paintaud
Therapeutic Drug Monitoring, 2017, pp.567-72. ⟨10.1097/FTD.0000000000000321⟩
Journal articles hal-01769813v1
Image document

Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti–TNF-α Antibodies after a Single Injection in Mice

Christophe Arnoult , Guillaume Brachet , Diana Cadena Castaneda , Nicolas Azzopardi , Christophe Passot
Journal of Immunology, 2017, 199 (2), pp.418-424. ⟨10.4049/jimmunol.1601246⟩
Journal articles hal-02019721v1

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group

Mira Tout , Anne-Laure Gagez , Stéphane Lepretre , Valérie Gouilleux-Gruart , Nicolas Azzopardi
Clinical Pharmacokinetics, 2017, 56 (6), pp.635 - 647. ⟨10.1007/s40262-016-0470-8⟩
Journal articles hal-01769807v1

Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients

Morgane Caulet , Thierry Lecomte , Olivier Bouché , Jérôme Rollin , Valérie Gouilleux-Gruart
Clinical Pharmacokinetics, 2016, 55 (11), pp.1381 - 1394. ⟨10.1007/s40262-016-0406-3⟩
Journal articles hal-01769811v1
Image document

Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab

Jérôme Rollin , Audrey Payancé , Valérie Gouilleux-Gruart , Michelle Boisdron-Celle , Nicolas Azzopardi
Pharmacogenomics, 2015, 16 (18), pp.2035-2043. ⟨10.2217/pgs.15.139⟩
Journal articles hal-02381189v1

Dose – response relationship of bevacizumab in hereditary hemorrhagic telangiectasia

Nicolas Azzopardi , Sophie Dupuis-Girod , David Ternant , Anne-Emmanuelle Fargeton , Isabelle Ginon
mAbs, 2015, 7 (3), pp.630 - 637. ⟨10.1080/19420862.2015.1022693⟩
Journal articles hal-01769884v1
Image document

Pharmacokinetics of adalimumab in Crohn’s disease

David Ternant , Konstantinos Karmiris , Séverine Vermeire , Celine Desvignes , Nicolas Azzopardi
European Journal of Clinical Pharmacology, 2015, 71 (9), pp.1155-1157. ⟨10.1007/s00228-015-1892-1⟩
Journal articles hal-01769822v1

Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies

Christophe Passot , Nicolas Azzopardi , Sylvaine Renault , Nadine Baroukh , Christophe Arnoult
mAbs, 2014, 5 (4), pp.614 - 619. ⟨10.4161/mabs.24815⟩
Journal articles hal-01769897v1
Image document

Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system

Laurent Guilleminault , Nicolas Azzopardi , Christophe Arnoult , Julien Sobilo , Virginie Hervé
Journal of Controlled Release, 2014, 196, pp.344-354. ⟨10.1016/j.jconrel.2014.10.003⟩
Journal articles hal-02376374v1

VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations

Virginie Herve , Nathalie Rabbe , Laurent Guilleminault , Flora Paul , Laurène Schlick
mAbs, 2014, 6 (6), pp.1638 - 1648. ⟨10.4161/mabs.34454⟩
Journal articles hal-01769888v1

Influence of plasma exchange on rituximab pharmacokinetics

Nicolas Azzopardi , Maud François , Emeline Laurent , Gilles Paintaud , Béatrice Birmelé
British Journal of Clinical Pharmacology, 2013, 76 (3), pp.486 - 488. ⟨10.1111/bcp.12167⟩
Journal articles hal-01769901v1

Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients

Nicolas Azzopardi , Therry Lecomte , David Ternant , Michele Boisdron-Celle , Friedrich Piller
Fundamental & Clinical Pharmacology, 2011, 25, pp.34-34
Journal articles hal-00616314v1

The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors

Agnes Maillet , Laurent Guilleminault , Etienne Lemarié , Stephanie Lerondel , Nicolas Azzopardi
Pharmaceutical Research, 2011, 28 (9), pp.2147 - 2156. ⟨10.1007/s11095-011-0442-5⟩
Journal articles hal-01769936v1

Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients

Nicolas Azzopardi , Thierry Lecomte , David Ternant , Michelle Boisdron-Celle , Friedrich Piller
Clinical Cancer Research, 2011, 17 (19), pp.6329 - 6337. ⟨10.1158/1078-0432.CCR-11-1081⟩
Journal articles hal-01769933v1
Image document

Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis

D Chu Miow Lin , D. Mulleman , N. Azzopardi , G Griffoul-Espitalier , P Valat
Scandinavian Journal of Rheumatology, 2010, 39 (1), pp.97 - 98. ⟨10.3109/03009740903177745⟩
Journal articles hal-01769938v1

Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis

D. Chu Miow Lin , D. Mulleman , N. Azzopardi , I. Griffoul-Espitalier , J.-P. Valat
Scandinavian Journal of Rheumatology, 2010, 39 (1), pp.97-98
Journal articles hal-00616813v1

Aerosoltherapy for lung tumors using the monoclonal antibody cetuximab

Agnes Maillet , Laurent Guilleminault , Nicolas Azzopardi , Jerome Montharu , Laurent Vecellio
Journal of Thoracic Oncology, 2009, 4 (9), pp.S600-S600
Journal articles hal-00616858v1

An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab

Nicolas Ceze , David Ternant , Friedrich Piller , Danielle Degenne , Nicolas Azzopardi
Therapeutic Drug Monitoring, 2009, 31 (5), pp.597-601
Journal articles hal-00521871v1

Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis

Juliette Thariat , Nicolas Azzopardi , Frederic Peyrade , Vincent Launay-Vacher , Jose Santini
Journal of Clinical Oncology, 2008, 26 (25), pp.4223-4225
Journal articles hal-00616934v1